Synonyms: CS-045 | Rezulin®
troglitazone is an approved drug (FDA (1997))
Compound class:
Synthetic organic
Comment: Troglitazone is an antidiabetic and anti-inflammatory drug.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Troglitazone is used to treat non-insulin-dependent diabetes mellitus (type II diabetes), along with diet and exercise. Treatment may also include insulin, a sulfonylurea drug, or metformin if necessary. However, use of this drug has been withdrawn in the UK, US and Japan due to adverse liver effects associated with its use. |
Mechanism Of Action and Pharmacodynamic Effects |
Troglitazone is an agonist with affinity for PPARγ and to a lesser extent PPARα. Activation of PPARs by troglitazone results in decreased NFκB, which reduces inflammation by regulating genes involved in the immune response. |